The Changyukang series cover genes related to targeted drugs, chemotherapy drugs, immunotherapy drugs and genetic risks. Using next-generation sequencing (NGS) technology of target gene capture, it comprehensively and accurately detects target gene capture exons and single nucleotide variations (SNV), short fragment insertion or deletion variations (InDel), gene copy number variations (CNV) and gene rearrangement/fusion within the intron range of standard spliceosomes. It simultaneously evaluates immunotherapy drugs and prognostic markers-MSI status to provide reference and guidance for clinical medication and genetic risk of patients with gastrointestinal tumors.